World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
120012
World Ranking
5642
National Ranking
3037

Michael D. Ezekowitz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael D. Ezekowitz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 433 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael D. Ezekowitz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael D. Ezekowitz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael D. Ezekowitz is affiliated with the Lankenau Institute for Medical Research in the United States. Their research primarily focuses on medicine, with a specialized emphasis on cardiology and cardiovascular medicine. Their work encompasses several subfields including internal medicine, infectious diseases, epidemiology, and molecular biology.

The scientist's main research topics are diverse but concentrated within cardiovascular health and disease management. These include atrial fibrillation management and outcomes, cardiac arrhythmias and treatments, venous thromboembolism diagnosis and management, antiplatelet therapy related to cardiovascular diseases, cardiac electrophysiology and arrhythmias, cardiac fibrosis and remodeling, and acute ischemic stroke management.

Among the recent publications authored or co-authored by Michael D. Ezekowitz are:

  • Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation, 2020, European Heart Journal
  • Drug Interactions Affecting Oral Anticoagulant Use, 2022, Circulation Arrhythmia and Electrophysiology
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation, 2020, Journal of the American Heart Association
  • Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial, 2020, TH Open
  • Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation, 2021, Cardiovascular Research

Frequent co-authors collaborating with Michael D. Ezekowitz include:

  • Stuart J. Connolly
  • Lars Wallentin
  • Daniel E. Singer
  • Salim Yusuf
  • Bernard J. Gersh

Michael D. Ezekowitz has published extensively in several key journals related to cardiovascular medicine. The most frequent venues include:

  • Circulation
  • European Heart Journal
  • Journal of the American Heart Association
  • The American Journal of Cardiology
  • Circulation Arrhythmia and Electrophysiology

Best Publications

  • Dabigatran versus warfarin in patients with atrial fibrillation

    Stuart J. Connolly;Michael D. Ezekowitz;John Eikelboom;Jonas Oldgren

  • 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

    Craig T. January;L. Samuel Wann;Joseph S. Alpert;Hugh Calkins

  • Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association

    Walter N. Kernan;Bruce Ovbiagele;Henry R. Black;Dawn M. Bravata

  • 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design

    Hugh Calkins;Karl Heinz Kuck;Riccardo Cappato;Josep Brugada

  • Edoxaban versus warfarin in patients with atrial fibrillation

    Robert P. Giugliano;Christian T. Ruff;Eugene Braunwald;Sabina A. Murphy

  • Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

    Christian T Ruff;Robert P Giugliano;Eugene Braunwald;Elaine B Hoffman

  • 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design

    Hugh Calkins;Karl Heinz Kuck;Riccardo Cappato;Josep Brugada

  • Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association

    Paul A. Heidenreich;Justin G. Trogdon;Olga A. Khavjou;Javed Butler

  • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

    Gregory G. Schwartz;Anders G. Olsson;Michael D. Ezekowitz;Peter Ganz

  • 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

    Craig T. January;L. Samuel Wann;Hugh Calkins;Lin Y. Chen

  • 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

    Craig T. January;L. Samuel Wann;Hugh Calkins;Lin Y. Chen

  • 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

    Craig T. January;L. Samuel Wann;Joseph S. Alpert

  • Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.

    Michael D. Ezekowitz;Samuel L. Bridgers;Kenneth E. James;Nathan H. Carliner

  • Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

    John W. Eikelboom;Lars Wallentin;Stuart J. Connolly;Mike Ezekowitz

  • Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial

    Lars Wallentin;Salim Yusuf;Michael D Ezekowitz;Marco Alings

  • 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

    L. Samuel Wann;Anne B. Curtis;Kenneth A. Ellenbogen;N.A. Mark Estes

  • 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

    Valentin Fuster;Lars E. Rydén;Davis S. Cannom;Harry J. Crijns

  • The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

    Paul A. Reilly;Thorsten Lehr;Sebastian Haertter;Stuart J. Connolly

  • Newly identified events in the RE-LY trial.

    Stuart J. Connolly;Michael D. Ezekowitz;Salim Yusuf;Paul A. Reilly

  • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the miracl study: a randomized controlled trial

    G.G Schwartz;A.G Olsson;M.D Ezekowitzet al

Frequent Co-Authors

Stuart J. Connolly
Stuart J. Connolly McMaster University
Lars Wallentin
Lars Wallentin Uppsala University
Salim Yusuf
Salim Yusuf McMaster University
John W. Eikelboom
John W. Eikelboom Population Health Research Institute
Agneta Siegbahn
Agneta Siegbahn Uppsala University
Jonathan P. Piccini
Jonathan P. Piccini Duke University
Daniel E. Singer
Daniel E. Singer Harvard University
Kenneth W. Mahaffey
Kenneth W. Mahaffey Stanford University
Gregg C. Fonarow
Gregg C. Fonarow University of California, Los Angeles
Bernard J. Gersh
Bernard J. Gersh Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Choosing a career in medicine doesn’t always mean pursuing a traditional MD. There are a wide range of online degrees and alternative paths available for those interested in the healthcare sector. For example, direct entry nursing programs can offer accelerated routes for students with a bachelor’s degree in another field, allowing them to kick-start a nursing career in less time.

If you’re interested in office-based medical careers, consider schools specializing in medical billing and coding schools with financial aid. These programs can lead to in-demand roles without extensive upfront costs, making them attractive for many working adults.

Not all nursing programs have rigid entrance exam requirements. You can explore do all nursing schools require the teas to find nursing schools that waive the TEAS or HESI, opening opportunities for more students.

For those interested in leadership and management roles, an healthcare administration associate degree online provides flexible options for building foundational knowledge and advancing in the ever-evolving healthcare industry.

Best Scientists Citing Michael D. Ezekowitz

Trending Scientists

Recently Published Articles